~~<i id='BDB686DC8C'><strike id='BDB686DC8C'><tt id='BDB686DC8C'><pre id='BDB686DC8C'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：focus 2025-09-29 15:14:55 Page View：1395

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Ed Silverman on new gene therapies, biosimilars, coffee, and more
Next article： What does generative AI mean for health care? We asked experts

leisure time

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

NIH study of ME/CFS points to clear biological hallmarks

AlisonSbranaattheNIHClinicalCenterinBethesda,Md.,participatesinastudyonmyalgicencephalomyelitis/chro